相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells
Donatella Treppiedi et al.
NEUROENDOCRINOLOGY (2020)
Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study
Dale Ding et al.
NEUROSURGERY (2019)
E-cadherin expression is associated with somatostatin analogue response in acromegaly
Eva Venegas-Moreno et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies
Tiziana Feola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles
Maria Caroline Alves Coelho et al.
SCIENTIFIC REPORTS (2019)
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly
Federico Gatto et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2019)
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms
Federico Gatto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
How to Position Pasireotide LAR Treatment in Acromegaly
Eva C. Coopmans et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)
Ammar Muhammad et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature
Joao Paulo Almeida et al.
JOURNAL OF NEUROSURGERY (2018)
How to improve effectiveness of pegvisomant treatment in acromegalic patients
M. Ragonese et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2018)
Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly
Maria Caroline Alves Coelho et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Postoperative Gamma Knife Radiosurgery for Cavernous Sinus-Invading Growth Hormone-Secreting Pituitary Adenomas
Eui Hyun Kim et al.
WORLD NEUROSURGERY (2018)
Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study
Ammar Muhammad et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY
Michael Buchfelder et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study
Ilan Shimon et al.
ENDOCRINE (2018)
Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization
Donatella Treppiedi et al.
ENDOCRINOLOGY (2018)
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database
Federico Gatto et al.
ENDOCRINE (2018)
Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance
Rosa Maria Paragliola et al.
PITUITARY (2017)
A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues
S. E. Franck et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas
Federico Gatto et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study
Andrea Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors
Harish Babu et al.
NEUROSURGERY (2017)
Biochemical investigations in diagnosis and follow up of acromegaly
Katharina Schilbach et al.
PITUITARY (2017)
Somatostatin receptor ligands in the treatment of acromegaly
Monica R. Gadelha et al.
PITUITARY (2017)
Pegvisomant in acromegaly: an update
A. Giustina et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2017)
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Annamaria Colao et al.
PITUITARY (2016)
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly
Iulia Potorac et al.
ENDOCRINE-RELATED CANCER (2016)
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly
Federico Gatto et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro
Alejandro Ibanez-Costa et al.
JOURNAL OF ENDOCRINOLOGY (2016)
Challenges in the diagnosis and management of acromegaly: a focus on comorbidities
Alin Abreu et al.
PITUITARY (2016)
Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly
Elena A. Christofides
PATIENT PREFERENCE AND ADHERENCE (2016)
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center
Susanna Bacigaluppi et al.
ENDOCRINE (2016)
Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
Herbert A. Schmid et al.
ENDOCRINE (2016)
RADIOTHERAPY VERSUS RADIOSURGERY IN TREATING PATIENTS WITH ACROMEGALY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Abd Moain Abu Dabrh et al.
ENDOCRINE PRACTICE (2015)
LONG-TERM TREATMENT WITH PEGVISOMANT AS MONOTHERAPY IN PATIENTS WITH ACROMEGALY: EXPERIENCE FROM ACROSTUDY
Pamela U. Freda et al.
ENDOCRINE PRACTICE (2015)
Cabergoline Use for Pituitary Tumors and Valvular Disorders
Renata S. Auriemma et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2015)
Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort
Caroline Sievers et al.
PITUITARY (2015)
ACROSTUDY: the Italian experience
S. Grottoli et al.
ENDOCRINE (2015)
Filamin A (FLNA) Plays an Essential Role in Somatostatin Receptor 2 (SST2) Signaling and Stabilization After Agonist Stimulation in Human and Rat Somatotroph Tumor Cells
E. Peverelli et al.
ENDOCRINOLOGY (2014)
Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly
S. J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
cAMP in the pituitary: an old messenger for multiple signals
Erika Peverelli et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2014)
Somatostatin receptor ligands and resistance to treatment in pituitary adenomas
Daniel Cuevas-Ramos et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2014)
EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly
Andrea Giustina et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism
Akira Shimatsu et al.
ENDOCRINE JOURNAL (2013)
β-Arrestin 1 and 2 and G Protein-Coupled Receptor Kinase 2 Expression in Pituitary Adenomas: Role in the Regulation of Response to Somatostatin Analogue Treatment in Patients With Acromegaly
Federico Gatto et al.
ENDOCRINOLOGY (2013)
Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas
Bernhard Mayr et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly
Federico Gatto et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
Antonio Bianchi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
Pegvisomant and cabergoline combination therapy in acromegaly
I. Bernabeu et al.
PITUITARY (2013)
Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience
Jessica Brzana et al.
PITUITARY (2013)
Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications
Thomas J. Wilson et al.
PITUITARY (2013)
Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-Analysis
Francisco Pita-Gutierrez et al.
PLOS ONE (2013)
Novel pathway for somatostatin analogs in patients with acromegaly
Monica R. Gadelha et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs
L. E. A. Wildemberg et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2013)
Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly
Ansgar Heck et al.
CLINICAL ENDOCRINOLOGY (2012)
Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas
Masako Kato et al.
ENDOCRINE JOURNAL (2012)
AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression
Leandro Kasuki et al.
ENDOCRINE-RELATED CANCER (2012)
Germline AIP Mutations in Apparently Sporadic Pituitary Adenomas: Prevalence in a Prospective Single-Center Cohort of 443 Patients
Laure Cazabat et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial
C. E. Higham et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway
Harvinder S. Chahal et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
A. J. van der Lely et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Management Options for Persistent Postoperative Acromegaly
Nestoras Mathioudakis et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2012)
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
Yasemin Tutuncu et al.
PITUITARY (2012)
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
Andrea Giustina et al.
PLOS ONE (2012)
Consensus Statement on the Standardization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays
David R. Clemmons
CLINICAL CHEMISTRY (2011)
Resistance to Somatostatin Analogs in Acromegaly
Annamaria Colao et al.
ENDOCRINE REVIEWS (2011)
The role of somatostatin and dopamine D2 receptors in endocrine tumors
Federico Gatto et al.
ENDOCRINE-RELATED CANCER (2011)
Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
Aart-Jan van der Lely et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Cotreatment with Pegvisomant and a Somatostatin Analog (SA) in SA-Responsive Acromegalic Patients
Michael Madsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Place of Cabergoline in Acromegaly: A Meta-Analysis
Laure Sandret et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Treatment of persistent and recurrent acromegaly
Lana A. Del Porto et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2011)
Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
Maria Fleseriu
PITUITARY (2011)
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Sebastian J. C. M. M. Neggers et al.
PITUITARY (2011)
Clinical, quality of life, and economic value of acromegaly disease control
A. Ben-Shlomo et al.
PITUITARY (2011)
Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)
Alberto Fernandez et al.
CLINICAL ENDOCRINOLOGY (2010)
A Potential Inhibitory Role for the New Truncated Variant of Somatostatin Receptor 5, sst5TMD4, in Pituitary Adenomas Poorly Responsive to Somatostatin Analogs
Mario Duran-Prado et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
The Expression of E-Cadherin in Somatotroph Pituitary Adenomas Is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response
Stine Lyngvi Fougner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Pasireotide and Octreotide Stimulate Distinct Patterns of sst2A Somatostatin Receptor Phosphorylation
Florian Poell et al.
MOLECULAR ENDOCRINOLOGY (2010)
Repeat Transsphenoidal Surgery for the Treatment of Remaining or Recurring Pituitary Tumors in Acromegaly
Shozo Yamada et al.
NEUROSURGERY (2010)
Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
Gherardo Mazziotti et al.
PITUITARY (2010)
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide AutogelA® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
Shlomo Melmed et al.
PITUITARY (2010)
Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA)
Harvinder S. Chahal et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial
Andrea Giustina et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Identification and Characterization of Two Novel Truncated but Functional Isoforms of the Somatostatin Receptor Subtype 5 Differentially Present in Pituitary Tumors
Mario Duran-Prado et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Acromegaly pathogenesis and treatment
Shlomo Melmed
JOURNAL OF CLINICAL INVESTIGATION (2009)
Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
Philippe Chanson et al.
CLINICAL ENDOCRINOLOGY (2008)
Clinicopathological features of growth hormone-producing pituitary adenomas: Difference among various types defined by cytokeratin distribution pattern including a transitional form
Abdulkader Obari et al.
ENDOCRINE PATHOLOGY (2008)
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
I. M. Holdaway et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
Giselle F. Taboada et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly
Robert D. Murray et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Correlation of in Vitro and in Vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy
Diego Ferone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Growth hormone response during oral glucose tolerance test:: The impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index
Ayman M. Arafat et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Pasireotide (SOM230): Development, mechanism of action and potential applications
Herbert A. Schmid
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization
Michael Grant et al.
MOLECULAR ENDOCRINOLOGY (2008)
Radiation therapy in acromegaly
Helen A. Shih et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2008)
Long-term efficacy and safety of combined treatment of somatostatin analogs and Pegvisomant in acromegaly
Sebastian J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly
Annamaria Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
IGF-I assays: current assay methodologies and their limitations
David R. Clemmons
PITUITARY (2007)
Medical progress: Acromegaly
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: Preferential expression of somatostatin receptor subtype 3
A. P. M. Casarini et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2006)
Predictors and rates of treatment-resistant tumor growth in acromegaly
GM Besser et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles
B Astruc et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'
P Nomikos et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro
LJ Hofland et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Effectiveness of secondary transnasal surgery in GH-secreting pituitary macroadenornas
M Kurosaki et al.
ENDOCRINE JOURNAL (2003)
Octreotide long-acting release (LAR) - A review of its use in the management of acromegaly
K McKeage et al.
DRUGS (2003)
分享论文
